The bioproduction market is projected to grow significantly, reaching a value of US$ 63,393.93 million by 2030, up from US$ 22,337.24 million in 2022.

This report outlines the current trends within the bioproduction sector, as well as the various factors that are influencing its growth, both positively and negatively.

Automation is playing a crucial role in enhancing the efficiency of cell therapy developers. It offers numerous advantages, such as minimizing contamination risks, ensuring consistent product quality, and lowering production costs. Several companies have introduced automated systems to facilitate this process. Notable examples include the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi, both of which are engineered to automate the majority of the sequential operations involved in CAR-T therapy production within a unified platform. The shift in cell therapy production from small-scale to large-scale operations globally has been notable. Furthermore, the transition of cell therapies from academic research to large-scale manufacturing and commercialization has escalated the demand for automation in production processes. The surge in research activities surrounding cell therapies has also contributed to the increased need for advanced manufacturing technologies. In response, numerous companies are developing solutions tailored to the digital requirements of both academic researchers and large biotech firms. For instance, in May 2019, GE Healthcare introduced the Chronicle web application, which supports the entire workflow of cell therapy. This automation software complies with good manufacturing practices (GMP) and is designed to enhance the development and manufacturing processes of complex cell therapies.

Additionally, companies are engaging in strategic partnerships and technological advancements to further automate cell therapy production. For example, in July 2020, Thermo Fisher Scientific Inc. collaborated with Lyell Immunopharma to create and refine processes aimed at developing effective cell therapies for cancer patients. This partnership focuses on enhancing T-cell functionality and establishing a comprehensive current good manufacturing practice (cGMP) compliant platform, which includes systems, software, reagents, consumables, and instruments. In March 2019, Lonza also teamed up with Sheba Medical Center in Israel to implement automated and closed CAR-T manufacturing using its Cocoon cell therapy platform. The growing trend of automation adoption among cell therapy manufacturers is expected to significantly propel market growth.

The bioproduction market is categorized by product types, including biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. In 2022, the biologics and biosimilars segment dominated the market share. However, the cell and gene therapies segment is anticipated to experience the highest compound annual growth rate (CAGR) from 2022 to 2030. Both cell therapy and gene therapy are interconnected fields within biomedical research and treatment, aiming to prevent, treat, or potentially cure various diseases.

Cell therapy focuses on treating diseases by restoring or modifying specific cell types outside the body before reintroducing them into the patient, or by utilizing cells to deliver therapies throughout the body. Conversely, gene therapy seeks to address diseases by restoring or introducing new genes into cells, either externally (ex vivo) or internally (in vivo). Gene therapies function by modifying genes in targeted cell types and integrating them into the body.

In terms of equipment, the bioproduction market is divided into consumables and accessories, downstream equipment, bioreactors, and upstream equipment. The consumables and accessories segment held the largest market share in 2022 and is projected to achieve the highest CAGR of 14.7% during the period from 2022 to 2030. Bioproduction relies heavily on various consumables and accessories, including cells, reagents, enzymes, and growth media. It also necessitates the use of disposable glassware and plasticware, such as petri dishes, test tubes, pipettes, automated pipette tips, and beakers. These items are collectively referred to as consumables and are essential at every stage of the cell therapy manufacturing process. They are also critical during quality control (QC) processes to ensure proper testing standards. Ongoing research and development within the biopharmaceutical sector are likely to drive an increased demand for consumables and accessories in the future, particularly as these items are often utilized in trial-and-error methodologies.

The bioproduction market is also segmented by end-users, which include biopharmaceutical companies, contract manufacturing organizations (CMOs), and others. The biopharmaceutical companies segment accounted for the largest market share in 2022. However, CMOs are expected to exhibit the highest CAGR of 14.7% from 2022 to 2030. Contract research organizations (CROs) provide essential support services to biotechnology, pharmaceutical, and medical device companies throughout the product development lifecycle. CROs specialize in research and offer significant value to pharmaceutical and biotechnology firms by reducing infrastructure and R&D costs, as well as expediting clinical trial processes. These organizations require a variety of services for disease diagnosis, gene mapping, and the identification of novel oncogenes or genetic mutations associated with various cancers.

Key sources utilized in the preparation of this report on the bioproduction market include the United States Food and Drug Administration (USFDA), the Institute for Clinical and Economic Review (ICER), and the Centers for Disease Control and Prevention (CDC).